Clinical Trial Update: The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of Newrabell (rabeprazole sodium) 10 mg twice daily in patients with refractory gastroesophageal reflux disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Newrabell (rabeprazole sodium)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Reflux Esophagitis | Phase 4 | Status: COMPLETED